|
Pipeline
Two lead products are being
developed as we have reduced our active agents down from a
complex lysate to individual molecules.
First, a peptide has been shown
in mice to provide efficacy against Gram-positive bacteria (S.
pneumoniae), Gram-negative bacteria (P. aeruginosa)
and fungal (A. fumigatus) pathogens.
Second a
combination of synthetic ligands has also shown efficacy
against every pathogen tested to date (Gram-positive
bacteria, Gram-negative bacteria and virus). This
combination could improve upon the peptide by having fewer
side effects in long-term use situations.
Mouse lungs
without (left) and with (right) treatment following a lethal
influenza challenge demonstrates how clean the lungs remain
when treated with our technology
Survival of
treated mice (red trace) compared to death in untreated mice
(black trace) in a lethal bacterial pneumonia challenge
|
 |
“This technology kills the invading pathogens
virtually on contact with the airways, even in
mice with suppressed immune systems.” Dr.
Brenton Scott
|
|
